Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Brazil Clarifies ANVISA Oversight Roles for Devices

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

Brazil’s National Surveillance Agency released an order mapping out the specific oversight roles for federal, state and local ANVISA branches for medical devices. Source: The GMP Letter

Continue ReadingBrazil Clarifies ANVISA Oversight Roles for Devices

FDA Flags Repeat Nonconformities at Zimmer Biomet Facility

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

In a rare exception to the FDA’s normal practice, the agency posted a Form 483 flagging several GMP and MDR nonconformities — most of which are repeat observations — at…

Continue ReadingFDA Flags Repeat Nonconformities at Zimmer Biomet Facility

FDA Warns German Device Firm Over Lack of Procedures

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

A four-day FDA inspection of Curasan’s manufacturing facility in Frankfurt, Germany revealed a lack of manufacturing and adverse event reporting procedures. Source: The GMP Letter

Continue ReadingFDA Warns German Device Firm Over Lack of Procedures

FDA Cites Digital Heat for Failing to Establish Design Procedures, CAPA

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

An FDA inspection of Digital Heat’s Tempe, Arizona facility conducted in December 2017 resulted in a nine-item Form 483 for failing to establish design procedures for the firm’s heated eye…

Continue ReadingFDA Cites Digital Heat for Failing to Establish Design Procedures, CAPA

China FDA to Issue New Device Standards Over Next Two Years

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

China’s Food and Drug Administration plans to revise more than 300 standards by 2020, according to a new two-year plan for bringing the country’s medical devices and in vitro diagnostics…

Continue ReadingChina FDA to Issue New Device Standards Over Next Two Years

Regulatory Hurdles for Design Changes Stall Boston Scientific’s Comeback

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

Boston Scientific is facing regulatory hurdles with its proposed manufacturing process and design changes to bring its transcatheter aortic valve back to the U.S. and EU markets. Source: The GMP…

Continue ReadingRegulatory Hurdles for Design Changes Stall Boston Scientific’s Comeback

India Releases Final Audit Fees for Notified Bodies

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

India’s Drugs Controller General released its final audit fees for notified bodies under its new medical device regulations. Source: The GMP Letter

Continue ReadingIndia Releases Final Audit Fees for Notified Bodies

Health Canada to Provide Assistance for SMEs to Meet MDSAP Deadline

  • Post author:Sam
  • Post published:March 8, 2018
  • Post category:The GMP Letter

Health Canada is sticking to its compliance deadline of Jan. 1, 2019, for devicemakers selling products in Canada to transition to the Medical Device Single Audit Program, but is making…

Continue ReadingHealth Canada to Provide Assistance for SMEs to Meet MDSAP Deadline

Prevail Therapeutics Grabs $75 Million to Advance Parkinson’s Disease Programs

  • Post author:Sam
  • Post published:March 7, 2018
  • Post category:BioPharma

Seven months after Prevail Therapeutics launched, the company has secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease. Source: BioSpace

Continue ReadingPrevail Therapeutics Grabs $75 Million to Advance Parkinson’s Disease Programs

Evotec and Sanofi Collaborate on Infectious Disease R&D Initiative

  • Post author:Sam
  • Post published:March 7, 2018
  • Post category:BioPharma

Sanofi SA and Evotec AG have teamed up to form an infectious disease research and development program. Source: BioSpace

Continue ReadingEvotec and Sanofi Collaborate on Infectious Disease R&D Initiative
  • Go to the previous page
  • 1
  • …
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.